文献速递肾小球疾病

膜性肾病:环孢素联合利妥昔单抗新型方案的初步研究

Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab.
PubMed 文献 · Kidney Int Rep · 2016-06-11

该初步研究纳入13例持续性重度蛋白尿(平均10.8 g/d)的高危原发性膜性肾病患者,接受利妥昔单抗联合环孢素诱导治疗6个月,随后第二周期利妥昔单抗及环孢素减量维持18个月。平均蛋白尿3个月下降65%、6个月下降80%,9个月时92%患者达完全或部分缓解,12个月时54%达完全缓解,2例复发,所有PLA2R抗体阳性者抗体清除,肾功能稳定,方案耐受良好。

要点

  • 利妥昔单抗联合环孢素诱导6个月后,平均蛋白尿较基线下降80%。
  • 9个月时92%患者达完全或部分缓解,12个月时54%达完全缓解。
  • 所有PLA2R抗体阳性患者均实现抗体清除,肾功能稳定,方案耐受良好。

核心结论

  • 该新型联合方案在13例高危膜性肾病患者中取得令人鼓舞的初步结果,平均蛋白尿显著下降且缓解率高。
  • 作者认为这些前瞻性收集的数据可为未来随机临床试验的设计和把握度计算提供参考,仍需正式随机试验比较该方案与现有疗法。

研究设计与样本

  • 初步研究,纳入13例持续性重度蛋白尿(平均10.8 g/d)定义的高危原发性膜性肾病患者。
  • 诱导期接受利妥昔单抗联合环孢素治疗6个月,随后第二周期利妥昔单抗及环孢素减量维持18个月。

主要发现

  • 平均蛋白尿3个月时较基线下降65%,6个月时下降80%。
  • 9个月时92%患者达完全或部分缓解,12个月时54%患者达完全缓解。
  • 试验期间2例患者复发。
  • 所有PLA2R抗体阳性患者均实现抗体清除,肾功能稳定,方案耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: There is broad consensus that high grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in patients with primary membranous nephropathy. Based on the fact that current regimens are not ideal due to short and long-term toxicity and propensity to relapse after treatment withdrawal, we developed a treatment protocol based on a novel combination of rituximab and cyclosporine which targets both the B and T cell limbs of the immune system. Herein, we report pilot study data on proteinuria, changes in autoantibody levels and renal function that offer a potentially effective new approach to treatment of severe membranous nephropathy. METHODS: Thirteen high-risk patients defined by sustained high-grade proteinuria (mean 10.8 g/d) received combination induction therapy with rituximab plus cyclosporine for 6 months, followed by a second cycle of rituximab and tapering of cyclosporine during an 18 month maintenance phase. RESULTS: Mean proteinuria decreased by 65% at 3 months and by 80% at 6 months. Combined complete or partial remission was achieved in 92% of patients by 9 months; 54% achieved complete remission at 12 months. Two patients relapsed during the trial. All patients with autoantibodies to PLA2R achieved antibody depletion. Renal function stabilized. The regimen was well tolerated. DISCUSSION: We report these encouraging preliminary results for their potential value to other investigators needing prospectively collected data to inform the design and power calculations of future randomized clinical trials. Such trials will be needed to formally compare this novel regimen to current therapies for membranous nephropathy.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Waldman M, Beck LH, Braun M, et al. Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab. Kidney Int Rep. 2016. PMID: 27942609

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。